Survey looks at risk analysis for health tech

A new survey aims to reveal baseline information about how healthcare facilities handle risk management for technology.

The survey, developed by the Healthcare Information and Management Systems Society (HIMSS) Medical Devices & Patient Safety Task Force and the Clinical Engineering and Information Technology (CE-IT) Community, focuses on the lifecycle of the technology, from acquisition to deployment, use, modification and retirement.

The information will enable the task force and the CE-IT Community to develop a Risk Analysis Resource Guide and help to:

  •  Determine the nature of the risk management process for organizations that report they have a process.
  • Determine the need for industry guidelines to assist all healthcare facilities in the prudent application of risk management to the technology life cycle.

The CE-IT Community is a collaboration among members of HIMSS, the Association for the Advancement of Medical Instrumentation and the American College of Clinical Engineering.

To take the survey, click here.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.